Novartis Plans Major Bio Plant

Novartis says it will spend about $700 million to build a biopharmaceutical drug manufacturing plant in Singapore. The planned facility will produce monoclonal antibody drugs designed to treat a range of diseases including cancers and rheumatoid arthritis. Novartis plans to start up the facility, which would feature a reactor larger than any in the company’s existing portfolio, in...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers